Study of Therapeutic Effects of Losartan for Sarcopenia Based on the F344xBN Rat Aging Model

Kang, Donghun; Park, Kideok; Kim, Dae-Young

doi:10.21873/invivo.13010

Cited by 5 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kang et al tested the effect of losartan in a rat model of sarcopenia. Male 4-week-old F344xBN rats were administered 0.6 g/L losartan diluted in drinking water over a period of 18 months [166]. Average muscle mass of the tibialis anterior (TA), soleus, and peroneus longus muscles was increased by losartan treatment combined with an exercise program, compared to exercise alone [166].…”

Section: Drug Repositioningmentioning

confidence: 99%

“…Male 4-week-old F344xBN rats were administered 0.6 g/L losartan diluted in drinking water over a period of 18 months [166]. Average muscle mass of the tibialis anterior (TA), soleus, and peroneus longus muscles was increased by losartan treatment combined with an exercise program, compared to exercise alone [166]. Interestingly, soleus (slow twitch type I) and peroneus longus (fast twitch type II) muscle mass was also increased without the need for an exercise program.…”

Section: Drug Repositioningmentioning

confidence: 99%

“…Interestingly, soleus (slow twitch type I) and peroneus longus (fast twitch type II) muscle mass was also increased without the need for an exercise program. Protein concentration assessment showed elevated levels of mTOR, Akt, and extracellular signal-regulated kinase (ERK, a branch of MAPK signaling [167]) in all muscles analyzed [166].…”

Section: Drug Repositioningmentioning

confidence: 99%

See 2 more Smart Citations

Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia

Kim,

Jung,

Williams

2023

Cells

View full text Add to dashboard Cite

Sarcopenia is a disease characterized by the progressive loss of skeletal muscle mass and function that occurs with aging. The progression of sarcopenia is correlated with the onset of physical disability, the inability to live independently, and increased mortality. Due to global increases in lifespan and demographic aging in developed countries, sarcopenia has become a major socioeconomic burden. Clinical therapies for sarcopenia are based on physical therapy and nutritional support, although these may suffer from low adherence and variable outcomes. There are currently no clinically approved drugs for sarcopenia. Consequently, there is a large amount of pre-clinical research focusing on discovering new candidate drugs and novel targets. In this review, recent progress in this research will be discussed, along with the challenges that may preclude successful translational research in the clinic. The types of drugs examined include mitochondria-targeting compounds, anti-diabetes agents, small molecules that target non-coding RNAs, protein therapeutics, natural products, and repositioning candidates. In light of the large number of drugs and targets being reported, it can be envisioned that clinically approved pharmaceuticals to prevent the progression or even mitigate sarcopenia may be within reach.

show abstract

Section: Drug Repositioningmentioning

confidence: 99%

Section: Drug Repositioningmentioning

confidence: 99%

Section: Drug Repositioningmentioning

confidence: 99%

See 1 more Smart Citation

Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia

Kim,

Jung,

Williams

2023

Cells

View full text Add to dashboard Cite

show abstract

“…A prospective study involving 740 older adults revealed a significant positive correlation between calcium intake and appendicular lean mass (ALM) [ 134 ]. Animal studies have also suggested that losartan may slow down muscle degeneration, promote clinical benefits, and provide protection for patients with sarcopenia [ 135 , 136 ].…”

Section: Introductionmentioning

confidence: 99%

Correlation between sarcopenia and esophageal cancer: a narrative review

Li,

Xie,

Xiao

et al. 2024

World J Surg Onc

View full text Add to dashboard Cite

Background In recent years, the research on the relationship between sarcopenia before and after the treatment of esophageal cancer, as well as its impact on prognosis of esophageal cancer, has increased rapidly, which has aroused people’s attention to the disease of patients with esophageal cancer complicated with sarcopenia. This review examines the prevalence of sarcopenia in patients with esophageal cancer, as well as the relationship between sarcopenia (before and after surgery or chemotherapy) and prognosis in patients with esophageal cancer. Moreover, we summarized the potential pathogenesis of sarcopenia and pharmacologic and non-pharmacologic therapies. Methods A narrative review was performed in PubMed and Web of Science using the keywords (“esophageal cancer” or “esophageal neoplasm” or “neoplasm, esophageal” or “esophagus neoplasm” or “esophagus neoplasms” or “neoplasm, esophagus” or “neoplasms, esophagus” or “neoplasms, esophageal” or “cancer of esophagus” or “cancer of the esophagus” or “esophagus cancer” or “cancer, esophagus” or “cancers, esophagus” or “esophagus cancers” or “esophageal cancer” or “cancer, esophageal” or “cancers, esophageal” or “esophageal cancers”) and (“sarcopenia” or “muscular atrophy” or “aging” or “senescence” or “biological aging” or “aging, biological” or “atrophies, muscular” or “atrophy, muscular” or “muscular atrophies” or “atrophy, muscle” or “atrophies, muscle” or “muscle atrophies”). Studies reporting relationship between sarcopenia and esophageal cancer were analyzed. Results The results of the review suggest that the average prevalence of sarcopenia in esophageal cancer was 46.3% ± 19.6% ranging from 14.4 to 81% and sarcopenia can be an important predictor of poor prognosis in patients with esophageal cancer. Patients with esophageal cancer can suffer from sarcopenia due to their nutritional deficiencies, reduced physical activity, chemotherapy, and the effects of certain inflammatory factors and pathways. When classic diagnostic values for sarcopenia such as skeletal muscle index (SMI) are not available clinically, it is also feasible to predict esophageal cancer prognosis using simpler metrics, such as calf circumference (CC), five-count sit-up test (5-CST), and six-minute walk distance (6MWD). Conclusions Identifying the potential mechanism of sarcopenia in patients with esophageal cancer and implementing appropriate interventions may hold the key to improving the prognosis of these patients.

show abstract

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies

Zheng,

Feng,

et al. 2024

Arch. Pharm. Res.

View full text Add to dashboard Cite

Study of Therapeutic Effects of Losartan for Sarcopenia Based on the F344xBN Rat Aging Model

Cited by 5 publications

References 41 publications

Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia

Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia

Correlation between sarcopenia and esophageal cancer: a narrative review

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies

Contact Info

Product

Resources

About